Lycia Therapeutics Files S-1 for Nasdaq Listing with Collaboration-Driven Revenue Model
Lycia Therapeutics, Inc. filed its S-1 on October 5, 2026, targeting a Nasdaq IPO. The targeted protein degradation company generated $41.2M in collaboration revenue in 2025 but zero product sales. R&D expenses totaled $36.5M. It has partnered with multiple global pharma firms.
51CFO view：CFOs of collaboration-revenue biotechs must master ASC 606’s licensing & milestone accounting, especially variable consideration estimation and constraint application. SEC will demand full contract clause mapping in footnotes — requiring CFOs to embed legal ops into finance workflows and deploy CLM-integrated ERP modules.
Lycia Therapeutics, Inc. filed its S-1 on October 5, 2026, targeting a Nasdaq IPO. The targeted protein degradation company generated $41.2M in collaboration revenue in 2025 but zero product sales. R&D expenses totaled $36.5M. It has partnered with multiple global pharma firms.
Source：SEC EDGAR · S-1 招股书备案